Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Contact information



Primary contact

Dr - -


Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number

MRC AML12 (modified)

Study information

Scientific title


Study hypothesis

Added as of 07/03/2007:
To compare two methods of administering all-Trans Retinoic Acid (ATRA) to patients with acute promyelocytic leukaemia (APL, FAB AML-M3) - either ATRA for 5 days only before the introduction of trial induction chemotherapy or continuous ATRA during induction chemotherapy until complete remission is achieved (or for a maximum of 60 days) with respect to differences in haemorrhagic complications, induction deaths, remission rate, remission duration and overall survival. To evaluate the role of ATRA in correcting the coagulopathy associated with APL. - To investigate the two methods of using ATRA therapy with respect to the sequence of change of laboratory parameters of coagulation and thrombolysis, and blood product usage. To evaluate cytogenetic and molecular monitoring of disease status with reference to the prediction of morphological leukaemia relapse.

Ethics approval

Not provided at time of registration.

Study design

Randomised controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Leukaemia (acute)


Four randomised comparisons:

At diagnosis:
1. S-DAT versus H-DAT
2. All-trans-retinoic acid (ATRA) versus not (except for acute promyelocytic leukaemia (APL) patients who will receive ATRA)

After course 3:
3. 4 versus 5 courses of total therapy
4. Bone marrow transplant (BMT) versus chemotherapy as the final course of therapy

Added 08/09/09: A trial with 250 patients would have a power of 50% to detect (at 2p=0.05) a 10% absolute difference in remission rate or long term survival between the two ATRA groups. If no difference were apparent between the two arms the possibility that one arm is greatly superior to the other (ie more than 50% better) would be eliminated. With extended collaboration (UK and internationally) to recruit a total of 500 patients the trial would have a power of about 90% to detect a 10% difference in remission rate and a power of about 50% to detect a 5% difference.

Intervention type



Not Specified

Drug names

Primary outcome measures

Added as of 07/03/2007:
Haemorrhagic complications, induction deaths, remission rate, remission duration, overall survival and the role of ATRA in correcting the coagulopathy associated with APL.

Secondary outcome measures

Not provided at time of registration

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Have one of the forms of AML
2. Are considered suitable for intensive chemotherapy
3. Are normally under the age of 60 years, but can be older as long as intensive therapy is considered suitable
4. Have given written informed consent

Participant type


Age group



Not Specified

Target number of participants


Participant exclusion criteria

Added as of 07/03/2007:
1. Previously received any treatment for APL
2. Other forms of AML (including CML in promyelocytic blast crisis)
3. Another concurrent active malignancy
4. Pregnant or consider the possibility of becoming pregnant during the course of treatment

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

UKCCCR Register Co-ordinator
United Kingdom

Sponsor information


Medical Research Council (MRC) (UK)

Sponsor details

20 Park Crescent
United Kingdom
+44 20 7636 5422

Sponsor type

Research council



Funder type

Research council

Funder name

Medical Research Council (MRC) (UK)

Alternative name(s)


Funding Body Type

private sector organisation

Funding Body Subtype

other non-profit


United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

1. 2001 results on relationships between age at diagnosis, clinical features, and outcome of therapy in
2. 2001 results on FLT3 duplication as a prognostic risk factor in chemotherapy in
3. 2005 results in
4. 2006 results in
5. 2009 results in
6. 2010 pooled analysis of prognostic significance of rare recurring chromosomal abnormalities in (see also ISRCTN17161961)

Publication citations

  1. Results

    Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK, Linch DC, No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials., Blood, 2005, 106, 10, 3658-3665, doi: 10.1182/blood-2005-03-1323.

  2. Results

    Rao A, Hills RK, Stiller C, Gibson BE, de Graaf SS, Hann IM, O'Marcaigh A, Wheatley K, Webb DK, Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials., Br. J. Haematol., 2006, 132, 5, 576-583, doi: 10.1111/j.1365-2141.2005.05906.x.

  3. Webb DK, Harrison G, Stevens RF, Gibson BG, Hann IM, Wheatley K, , Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia., Blood, 2001, 98, 6, 1714-1720.

  4. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC, The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials., Blood, 2001, 98, 6, 1752-1759.

  5. Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, Duncombe A, Gibson B, Wheatley K, Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial., J. Clin. Oncol., 2010, 28, 4, 586-595, doi: 10.1200/JCO.2009.22.9088.

  6. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK, , Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials., Blood, 2010, 116, 3, 354-365, doi: 10.1182/blood-2009-11-254441.

Additional files

Editorial Notes